Abstract
When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 761-766 |
| Number of pages | 6 |
| Journal | Cancer Cell |
| Volume | 38 |
| Issue number | 6 |
| DOIs |
|
| Publication status | Published - Dec 14 2020 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier Inc.
Funding
The consortium would like to acknowledge the writing committee who drafted this manuscript: Dimpy P. Shah, MD, PhD; Sanjay Mishra, MS, PhD; and Jeremy L. Warner, MD, MS. The consortium would also like to acknowledge the early contributions of Dr. Nicole M. Kuderer, MD, and Dr. Donna R. Rivera, PharmD, MsC. We thank all members of the CCC19 steering committee: Toni K. Choueiri, MD; Petros Grivas, MD, PhD; Gilberto de Lima Lopes, Jr., MD, MBA; Corrie A. Painter, PhD; Solange Peters, MD, PhD; Brian I. Rini, MD; Dimpy P. Shah, MD, PhD; Michael A. Thompson, MD, PhD; and Jeremy L. Warner, MD, MS, for their invaluable guidance of the CCC19 consortium. This study was partly supported by grants from the American Cancer Society and Hope Foundation for Cancer Research ( MRSG-16-152-01-CCE ; to D.P.S.) and the National Cancer Institute ( P30 CA054174 to D.P.S.; P30 CA068485 to J.L.W. and S.M.; and U01 CA231840 to J.L.W.). REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support ( UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. The consortium would like to acknowledge the writing committee who drafted this manuscript: Dimpy P. Shah, MD, PhD; Sanjay Mishra, MS, PhD; and Jeremy L. Warner, MD, MS. The consortium would also like to acknowledge the early contributions of Dr. Nicole M. Kuderer, MD, and Dr. Donna R. Rivera, PharmD, MsC. We thank all members of the CCC19 steering committee: Toni K. Choueiri, MD; Petros Grivas, MD, PhD; Gilberto de Lima Lopes, Jr. MD, MBA; Corrie A. Painter, PhD; Solange Peters, MD, PhD; Brian I. Rini, MD; Dimpy P. Shah, MD, PhD; Michael A. Thompson, MD, PhD; and Jeremy L. Warner, MD, MS, for their invaluable guidance of the CCC19 consortium. This study was partly supported by grants from the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE; to D.P.S.) and the National Cancer Institute (P30 CA054174 to D.P.S.; P30 CA068485 to J.L.W. and S.M.; and U01 CA231840 to J.L.W.). REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. J.L.W. reports having received personal fees from Westat and IBM Watson Health and equity in HemOnc.org LLC outside the submitted work.
| Funders | Funder number |
|---|---|
| Hope Foundation for Cancer Research | MRSG-16-152-01-CCE |
| NCATS/NIH | |
| National Institutes of Health | |
| American Cancer Society | |
| National Cancer Institute | P30CA177558, P30 CA068485, P30 CA054174, U01 CA231840 |
| National Center for Advancing Translational Sciences | |
| Vanderbilt Institute for Clinical and Translational Research | UL1 TR000445 |
| Korean Foundation for Cancer Research |
ASJC Scopus Subject Areas
- Oncology
- Cancer Research
